	US 12,221,462 B2
	Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells
Cyril Alkis Konto, San Francisco, CA (US); and Amina Zinai, Paris (FR)
Assigned to Allogene Therapeutics, Inc., South San Francisco, CA (US); and Les Laboratoires Servier, Suresnes (FR)
Filed by Allogene Therapeutics, Inc., South San Francisco, CA (US); and Les Laboratoires Servier, Suresnes (FR)
Filed on Oct. 10, 2023, as Appl. No. 18/484,244.
Application 18/484,244 is a continuation of application No. 16/175,663, filed on Oct. 30, 2018, abandoned.
Claims priority of provisional application 62/750,215, filed on Oct. 24, 2018.
Claims priority of provisional application 62/716,898, filed on Aug. 9, 2018.
Claims priority of provisional application 62/579,426, filed on Oct. 31, 2017.
Prior Publication US 2024/0041930 A1, Feb. 8, 2024
Int. Cl. A61K 35/17 (2015.01); A61K 31/664 (2006.01); A61K 31/7076 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01)

CPC C07K 14/70578 (2013.01) [A61K 31/664 (2013.01); A61K 31/7076 (2013.01); A61K 38/177 (2013.01); A61K 38/1774 (2013.01); A61K 39/001102 (2018.08); A61K 39/3955 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 16/2803 (2013.01); C07K 16/2893 (2013.01); C07K 16/3061 (2013.01); C12N 5/0636 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); A61K 2239/23 (2023.05); A61K 2239/26 (2023.05); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05); A61K 2300/00 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2506/11 (2013.01)]

20 Claims

1. A method of treating a subject who has refractory and/or relapsed non-Hodgkin's lymphoma comprising administering to the subject allogeneic chimeric antigen receptor (CAR)-T cells (CAR-T cells) comprising an anti-human CD19 4-1BB/CD3zeta CAR, wherein the method comprises administering to the subject at least one unit dose of 120×10⁶cells/dose or 360×10⁶cells/dose, and wherein the anti-human CD19 4-1BB/CD3zeta CAR comprises the amino acid sequence of SEQ ID NO: 1.